SCHEMBL3305698

SCHEMBL3305698

Cc1cc2cc(N(C(C(=O)O)C(C)(C)C)S(=O)(=O)c3cc(Cl)cc(Cl)c3)ccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.38
MAOA P21397 6/20 0.35
MAOB P27338 6/20 0.35
HSD11B1 P28845 2/20 0.33
MAPT P10636 5/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.32
ALDH1A1 P00352 3/20 0.32
ITGA4 P13612 1/20 0.32
SCN9A Q15858 1/20 0.32
P2RX3 P56373 1/20 0.32
F7 P08709 1/20 0.31
F3 P13726 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300480 0.84 PTGS2 (0.37) PTGS2MAOAHSD11B1NPC1P2RX3
SCHEMBL3299041 0.83 KDM4E (0.39) PTGS2HSD11B1MAPTSMN1; SMN2KDM4E
SCHEMBL3297369 0.83 S1PR1 (0.44) MAOBMEN1KMT2A
SCHEMBL3299972 0.81 PTGS2 (0.34) PTGS2HSD11B1MAPTNPC1RAB9A
SCHEMBL3302816 0.81 MGAM (0.35) HSD11B1GAAF7F3
SCHEMBL3301653 0.80 ALDH1A1 (0.36) HSD11B1ALDH1A1ITGA4
SCHEMBL3297160 0.80 MGAM (0.34) HSD11B1MAPTGAALMNAF7
SCHEMBL3294496 0.79 PTGS2 (0.34) PTGS2HSD11B1NPC1F7F3
SCHEMBL3298532 0.78 MGAM (0.33) HSD11B1GAAF7F3
SCHEMBL3300940 0.77 HTR6 (0.41) MAPTKDM4EMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121600-B1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2012-07-18 EP disclosed
US-20100093703-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093703-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PYGL, PYGM, G6PC1 PTGS2 3933/4885MAOA 741/4885MAOB 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.